Synopsis A clinical study demonstrates that Dorzagliatin offers a unique opportunity to improve the glucose sensor function of glucokinase and achieve good glycaemic control in patients with type 2 diabetes. It is achieved without increasing the risk of hypoglycaemia, dyslipidaemia, hepatic injury, and weight gain. This week's ' MED FACT ' discusses a clinical trial from The Lancet Diabetes & Endocrinology, “ Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study ”. May 2018.
Authors : Zhu D; Gan S; Liu Y; Ma J; Dong X; Song W; Wang G; Zhao W; Zhang Q; Li Y; Fang H . Key Takeaways Dorzagliatin is an effective treatment for patients with Type 2 Diabetes. Objective Study Type Participants To analyse to assess the efficacy and safety of dorzagliatin monotherapy at different doses in patients with…
